Investors stump up €15.5m more for Affimed
This article was originally published in Scrip
Executive Summary
The German antibody therapeutics company Affimed has closed a €15.5 million series D financing round led by existing investors Aeris Capital, BioMedInvest, LSP Life Science Partners, Novo Nordisk and Orbimed, bringing up to €68.5 million the total amount of venture capital it has raised since it was founded in 2000. The money will be used for the clinical development of its two lead candidates, AFM11 and AFM13, which are currently in preclinical and Phase I trials, respectively.